Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August

The companies anticipate clinical studies to begin in August, subject to regulatory approvals

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY

Pfizer registers Q4FY21net profit at Rs 100 Cr

Revenue from operations for the year ended March 31, 2021 is ?2,239 crore

Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr

The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.

FDA grants priority review to Merck’s KEYTRUDA and KEYTRUDA QLEX combos with Padcev for muscle-invasive bladder cancer

The submissions are supported by data from the Phase 3 KEYNOTE-905 trial

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting

AstraZeneca to lower cost of medicines for American patients

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price

Bristol Myers Squibb to present new cardiovascular data at ESC Congress 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion